MK-677, also known as ibutamoren, is an orally active, non-peptide growth hormone secretagogue that the published record describes as a ghrelin mimetic: rather than supplying growth hormone, it acts on the growth hormone secretagogue receptor (GHSR-1a) in the hypothalamus and pituitary to prompt release of the body's own stored hormone. The literature reports that this preserves the natural pulsatile rhythm of secretion, raises both growth hormone and insulin-like growth factor 1 (IGF-1), and, because the molecule is a small stable non-peptide with a roughly 24-hour half-life, sustains that signal from a single daily oral dose. The honest bottom line on status comes first: MK-677 is an investigational research compound studied in clinical trials, not an approved marketed therapeutic.
MK-677 is an orally active non-peptide ghrelin mimetic that binds GHSR-1a to stimulate the body's own pulsatile growth hormone and IGF-1 release, and it remains an investigational compound with no marketing approval.
The published literature places MK-677 in the pharmacological class of growth hormone secretagogues, compounds that stimulate the body's own growth hormone secretion rather than acting as the hormone itself, and within that class it is documented as a non-peptide, orally bioavailable secretagogue. That non-peptide structure is the load-bearing chemical distinction: where peptide secretagogues are degraded in the digestive tract and require injection, the small-molecule backbone resists enzymatic breakdown and survives passage through the gut.
MK-677 is chemically a non-peptide spiropiperidine-derivative growth hormone secretagogue and a ghrelin mimetic, distinct from the androgen-receptor pathway it is frequently and inaccurately grouped with.
What makes the mimicry work, according to the published mechanism, is that MK-677 binds GHSR-1a, the same receptor ghrelin evolved to target, which is densely expressed in the arcuate nucleus of the hypothalamus and in the somatotroph cells of the anterior pituitary. From the receptor's perspective the synthetic molecule and the natural hormone produce a comparable activating signal, and the literature describes the effect acting from more than one point in the regulatory system rather than the pituitary alone.
By occupying GHSR-1a and raising intracellular calcium in pituitary somatotrophs, MK-677 reproduces ghrelin's activating cascade while also reportedly increasing GHRH and blunting somatostatin, driving endogenous growth hormone release through the body's existing signaling architecture.
The literature reports that once MK-677 stimulates the pituitary, the released growth hormone circulates to the liver and peripheral tissues and prompts production of IGF-1, the principal mediator of many of growth hormone's anabolic actions. The documented value of the compound therefore rests heavily on this secondary IGF-1 elevation rather than on the growth hormone spike alone, and clinical study has recorded the rise as sustained across the day rather than transient.
MK-677 drives a sustained IGF-1 elevation, reported in clinical study commonly in the range of one-third to more than one-half above baseline, that plateaus under negative feedback rather than rising without limit.
Oral activity is the practical hallmark documented for MK-677, and the published mechanism traces it directly to the molecule being non-peptide: where peptide secretagogues are cleaved by digestive enzymes before absorption and so must be injected, the small organic structure is reported to pass intact through the gastrointestinal tract into circulation. The defining kinetic property in the literature is a long elimination half-life of approximately 24 hours, unusually durable for a secretagogue.
MK-677 is orally bioavailable because its non-peptide structure resists digestive enzymes, and its approximately 24-hour elimination half-life, cleared through hepatic metabolism, is what the literature reports as sufficient for once-daily dosing.
Growth hormone is naturally secreted in discrete bursts rather than a steady stream, with the largest pulses occurring during deep sleep, and the published mechanism treats this rhythm as biologically meaningful because tissues respond differently to peaks and troughs than to a flat continuous level. What the literature documents as distinguishing about MK-677 is that it amplifies output while largely preserving that pulsatile architecture, raising pulse height and total hormone secreted without erasing the rhythmic rise-and-fall the body uses.
MK-677 amplifies growth hormone output while largely preserving the natural pulsatile rhythm, a pattern the literature contrasts with the flatter, non-physiological exposure produced by injected recombinant growth hormone.
The clearest framing in the literature is by mechanism: MK-677 is a secretagogue that stimulates the body's own glands to release stored growth hormone, whereas recombinant growth hormone is direct replacement supplied from outside the body, and injectable peptide secretagogues share the secretagogue strategy but differ in route and duration. Because a secretagogue works through the pituitary, the documented effect depends on a functioning gland, while direct replacement bypasses it.
| Property | MK-677 | Injectable peptide secretagogues | Recombinant GH |
|---|---|---|---|
| Mechanism | Stimulates endogenous release | Stimulates endogenous release | Direct hormone replacement |
| Route | Oral, once daily | Subcutaneous, often multiple/day | Injection |
| Duration | Roughly day-long half-life | Much shorter | N/A (direct supply) |
| Feedback | Operates within GH/IGF-1 feedback | Operates within feedback | Overrides feedback |
MK-677's oral once-daily route and roughly 24-hour half-life distinguish it from the repeated subcutaneous injections and shorter action of peptide secretagogues, while as a secretagogue it remains within the body's GH and IGF-1 feedback loop that direct recombinant growth hormone overrides.
A sustained rise in growth hormone and IGF-1 is documented to reach across multiple body systems because these signaling molecules act on receptors found throughout the body. The published picture is deliberately two-sided: the same elevation that promotes lean tissue and bone activity also carries recognized unwanted effects, which is why the literature frames it as a whole physiological state rather than a list of benefits.
A sustained rise in growth hormone and IGF-1 acts across muscle, bone, connective tissue, sleep, and metabolism, and the literature documents the same elevation carrying recognized adverse effects including fluid retention, joint discomfort, increased appetite, and altered insulin sensitivity and blood glucose.
The published record places MK-677 as an investigational research compound rather than an approved medicine: it has been the subject of clinical trials over a period of years, studied for raising growth hormone and IGF-1 in contexts such as age-related GH decline, muscle wasting, and bone health, but it has not advanced to approval as a marketed therapeutic. That status is not a footnote; it determines how every claim about the compound should be weighed, because safety and efficacy rest on a limited investigational evidence base rather than the full approval process.
MK-677 is an investigational research compound with no marketing approval, typically sold labeled as a research chemical not for human consumption, and prohibited under anti-doping rules for athletes subject to those frameworks.
Educational use only. This article describes what the published scientific and clinical literature reports about MK-677. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
